

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3474711

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GENTA INCORPORATED	09/06/2013
RECEIVING PARTY DATA	
Name:	HERON THERAPEUTICS, LLC
Street Address:	4747 EXECUTIVE DRIVE, SUITE 510
Internal Address:	C/O TANG CAPITAL PARTNERS, LP
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14199574
CORRESPONDENCE DATA	
Fax Number:	(617)832-7000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-832-1754
Email:	rcc@foleyhoag.com
Correspondent Name:	DAVID P. HALSTEAD
Address Line 1:	155 SEAPORT BLVD., SEAPORT WEST
Address Line 2:	FOLEY HOAG LLP
Address Line 4:	BOSTON, MASSACHUSETTS 02210-2600
ATTORNEY DOCKET NUMBER:	GFH-014.02
NAME OF SUBMITTER:	DAVID P. HALSTEAD
SIGNATURE:	/David P. Halstead/
DATE SIGNED:	08/07/2015
Total Attachments: 12	
source=GFH01402_EXECUTED_ASSIGNMENT_GENTA_INCORPORATED_TO_HERON_THERAPEUTICS_LLC#pag	
source=GFH01402_EXECUTED_ASSIGNMENT_GENTA_INCORPORATED_TO_HERON_THERAPEUTICS_LLC#pag	
source=GFH01402_EXECUTED_ASSIGNMENT_GENTA_INCORPORATED_TO_HERON_THERAPEUTICS_LLC#pag	
source=GFH01402_EXECUTED_ASSIGNMENT_GENTA_INCORPORATED_TO_HERON_THERAPEUTICS_LLC#pag	

source=GFH01402_EXECUTED_ASSIGNMENT_GENTA_INCORPORATED_TO_HERON_THERAPEUTICS_LLC#pag
source=GFH01402_EXECUTED_ASSIGNMENT_GENTA_INCORPORATED_TO_HERON_THERAPEUTICS_LLC#pag
source=GFH01402_EXECUTED_ASSIGNMENT_GENTA_INCORPORATED_TO_HERON_THERAPEUTICS_LLC#pag
source=GFH01402_EXECUTED_ASSIGNMENT_GENTA_INCORPORATED_TO_HERON_THERAPEUTICS_LLC#pag
source=GFH01402_EXECUTED_ASSIGNMENT_GENTA_INCORPORATED_TO_HERON_THERAPEUTICS_LLC#pag
source=GFH01402_EXECUTED_ASSIGNMENT_GENTA_INCORPORATED_TO_HERON_THERAPEUTICS_LLC#pag
source=GFH01402_EXECUTED_ASSIGNMENT_GENTA_INCORPORATED_TO_HERON_THERAPEUTICS_LLC#pag
source=GFH01402_EXECUTED_ASSIGNMENT_GENTA_INCORPORATED_TO_HERON_THERAPEUTICS_LLC#pag

PATENT, TRADEMARK, AND INTELLECTUAL PROPERTY RIGHTS ASSIGNMENT

THIS PATENT, TRADEMARK, AND INTELLECTUAL PROPERTY ASSIGNMENT is effective as of September 30, 2013.

WHEREAS, GENTA INCORPORATED, a Delaware corporation located at c/o Cozen O'Connor, 1201 N. Market Street, Suite 1400, Wilmington, DE 19801, (the "Assignor"), is the owner of the patents and patent applications listed on Schedule A hereto (the "Patents") and the trademarks and trademark applications listed on Schedule A (the "Trademarks") and those Intellectual Property Rights defined in the Agreement (further defined below) including those listed on Schedule A;

WHEREAS, GEORGE MILLER as chapter 7 trustee (the "Trustee") for the Assignor has agreed to transfer the Intellectual Property Rights as set forth in the Asset Purchase Agreement dated as of September 30, 2013 (the "Agreement"), including Assignor rights in and to the Patents and Trademarks as set forth in the Agreement to HERON THERAPEUTICS, LLC, a Delaware limited liability company located at c/o Tang Capital Partners, LP, 4747 Executive Drive, Suite 510, San Diego, California 92121 or its designee (the "Assignee"), and Assignee has agreed to accept such assignment, on the terms and conditions set forth in the Agreement;

WHEREAS, Assignor is presently the debtor in a pending chapter 7 bankruptcy case filed pursuant to Title 11 of the United States Code, 11 U.S.C. § 101, *et seq.* (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"), case number 12-12269 (the "Bankruptcy Case").

WHEREAS, the Bankruptcy Court appointed the Trustee as the chapter 7 trustee for the Assignor. Pursuant to sections 541 and 704 of the Bankruptcy Code, upon the commencement of the Bankruptcy Case, all property of the Assignor became assets of the Assignor's chapter 7 estate, under the control of the Trustee.

WHEREAS, pursuant to the Motion Of The Trustee For Entry Of A Bidding Procedures Order (I) Approving the Bidding Procedures, (II) Authorizing the Trustee and Heron Therapeutics, LLC to Enter Into the Stalking Horse Agreement, and (III) Granting Related Relief, dated July 26, 2013 (Docket No. 130), the Trustee sought approval from the Bankruptcy Court to sell substantially all of Assignor's assets to, and enter into the Asset Purchase Agreement (as defined below) with, the Assignee.

WHEREAS, after a hearing on July 26, 2013, the Bankruptcy Court entered an order (Docket No. 133) authorizing the Trustee and the Assignee to enter into the Agreement and take other actions related thereto, subject to receipt of higher and better offers.

WHEREAS, after a hearing on September 26, 2013, the Bankruptcy Court approved the sale to Assignee pursuant to the Agreement.

WHEREAS, the parties wish to herein memorialize said assignment, transfer and sale of

the Patents and Trademarks to Assignee in a form for recording in the United States Patent and Trademark Office and non-US counterparts thereof in non-US jurisdictions which exercise authority over any of the Intellectual Property Rights including the Patents and Trademarks.

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN, be it known that for good and valuable consideration, the receipt and legal sufficiency of which is hereby acknowledged, and pursuant to the terms and conditions of the Agreement, the Trustee hereby sells, assigns, transfers, and conveys to Assignee, all right, title and interest in and to the Intellectual Property Rights, including the Patents, and any continuations, continuations-in-part, divisions, reissues, reexaminations, extensions, and foreign patents and patent applications thereof, and any rights to file applications claiming the benefit of one or more of the Intellectual Property Rights including the Patents and receive patents that issue from said applications and from said applications and from applications included in the Patents and patent applications and pending inventions of Intellectual Property Rights as yet unprepared or unfiled, together with all claims for past and future damages by reason of infringement of the same, and together with the right to sue for past and future damages;

AND, the Trustee hereby assigns, transfers, conveys and delivers to Assignee and its successors and assigns, all of its right, title and interest throughout the world in, to and under the Trademarks, all goodwill associated therewith or symbolized thereby, all common law rights thereto, all registrations that have been or may be granted thereon, all applications for registration thereof, all records and files relating to said Trademarks and all foreign counterparts thereof, together with the right to sue and recover damages for future or past infringements thereof and to fully and entirely stand in the place of the Trustee in all matters related thereto.

AND, the Trustee hereby assigns the domain names listed in Schedule A (the "Domain Names") and agrees to cooperate fully with Assignee to execute the electronic transfer of the Domain Names from the Trustee's account(s) with the applicable domain name registrars to the Assignee's account(s) with the applicable domain name registrars. The Trustee further agrees to duly execute and deliver or cause to be executed and delivered all other instruments of sale, conveyance, transfer and assignment, and notices, releases, acquittances and other documents and perform such further acts as may be necessary to convey, transfer, assign, deliver to, consolidate, vest and record in Assignee, full ownership of the Domain Names and other rights conveyed herewith, and to perfect Assignee's rights in and to the Domain Names, including, without limitation, providing authorization to the applicable domain name registrars and their respective designees;

AND, the Trustee hereby requests the Director of the United States Patent and Trademark Office (the "Director"), as well as his or her non-US counterparts in the non-US jurisdictions which exercise authority over any of the Intellectual Property Rights including the Patents and Trademarks to record this Patent, Trademark and Intellectual Property Rights Assignment. The Trustee hereby further requests the Director and his or her non-US counterparts to issue any and all patents, trademarks, or other intellectual property resulting from Intellectual Property Rights, inventions, Patents or from applications claiming the benefit of one or more of the Intellectual Property Rights including the Patents and Trademarks to Assignee as assignee of the entire interest therein.

At any time, and from time to time at Assignee's request, the Trustee agrees to execute further documents and instruments and to do such other acts as may be necessary or reasonably

requested by Assignee to more effectively vest full title in and to the Patents and Trademarks in the Assignee, including without limitation the Trademark Assignment attached hereto. This Assignment shall be binding upon and shall inure to the benefit of the respective successors and permitted assigns of the Trustee, the Assignor and Assignee.

(The signatures of the parties are contained on the following page.)

IN WITNESS WHEREOF, the Trustee and Assignee have caused this Patent, Trademark, and Intellectual Property Assignment to be executed by their authorized representatives as of the date first set forth above.

By: *George Miller*
George Miller,
as chapter 7 trustee of Genta Incorporated


Pennsylvania
STATE OF ~~DELAWARE~~ COUNTY OF Philadelphia

The foregoing instrument was acknowledged before me this 07th day of September, 2013, by George Miller, the chapter 7 Trustee of Genta Incorporated, a Delaware corporation, on behalf of said corporation. He ~~she~~ is personally known to me or produced _____ as identification.


Lisa A. Gangloff
Notary Public

Lisa A. Gangloff
Typed, printed or stamped name of Notary Public

My Commission Expires: 11/29/2014



HERON THERAPEUTICS, LLC

By: 
Name:
Title:

STATE OF CALIFORNIA, COUNTY OF _____

The foregoing instrument was acknowledged before me this ____ day of _____ 2013, by _____ the _____ of Heron Therapeutics, LLC, a Delaware limited liability company, on behalf of said company. He/she is personally known to me or produced _____ as identification.

Notary Public

Typed, printed or stamped name of Notary Public

My Commission Expires: _____

ACKNOWLEDGMENT


State of California
County of San Diego

On September 18, 2013 before me, Amanda Barnes, Notary Public
(insert name and title of the officer)

personally appeared Kevin Tang
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are
subscribed to the within instrument and acknowledged to me that he/she/they executed the same in
his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the
person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing
paragraph is true and correct.

WITNESS my hand and official seal.



Signature Amanda Barnes (Seal)

Schedule A

Genta Incorporated
Schedule 2.1(e) Purchased IP

Patents and Trademarks

PATENTS									
FILE NUMBER	STATUS	COUNTRY	TITLE/MARK	APPLICATION NUMBER	DATE FILED	PATEIN IN REG. NUMBER	GRANT/REG. DATE		
GEN0001-00	Issued	US	PHARMACEUTICAL GALLIUM COMPOSITIONS AND METHODS	11/551,422	20-Oct-06	7354952	8-Apr-08		
GEN0201-01CT	Issued	US	PHARMACEUTICAL GALLIUM COMPOSITIONS AND METHODS	12/043,997	11-Apr-08	7456215	25-Nov-08		
GEN0001-01CT	Issued	US	PHARMACEUTICAL GALLIUM COMPOSITIONS AND METHODS	12/046,128	11-Apr-08	7842724	10-Nov-10		
GEN0001-00KR	Pending	KR	PHARMACEUTICAL GALLIUM COMPOSITIONS AND METHODS	KR20087016660	20-Oct-06				
GEN-0001-00BR	Pending	BR	PHARMACEUTICAL GALLIUM COMPOSITIONS AND METHODS	BR0618096	20-Oct-06				
GEN-0001-00CA	Pending	CA	PHARMACEUTICAL GALLIUM COMPOSITIONS AND METHODS	CA2626029	20-Oct-06				
GEN-0001-00EA	Pending	EA	PHARMACEUTICAL GALLIUM COMPOSITIONS AND METHODS	EA20080601261	20-Oct-06				
	Pending	CA	PHARMACEUTICAL GALLIUM COMPOSITIONS AND METHODS	CA2722571	29-Apr-09				
	Pending	JP	PHARMACEUTICAL GALLIUM COMPOSITIONS AND METHODS	JP2011519659	29-Apr-09				
	Pending	KR	PHARMACEUTICAL GALLIUM COMPOSITIONS AND METHODS	KR20107029667	29-Apr-09				
	Pending	RU	PHARMACEUTICAL GALLIUM COMPOSITIONS AND METHODS	RU20100144180	29-Apr-09				
GEN0030-00US	Issued	US	Method of Preparing 2'-O-methyl cytidine monomers useful in oligonucleotide synthesis	07/893,374	5-Jun-92	5606049	25-Feb-97		
GEN0035-00NZ	Issued	NZ	Improved Process for the Synthesis of Oligomers	240325	21-Oct-91	240325	6-Dec-93		
GEN0037-00NZ	Issued	NZ	Anti-Sense Nucleoside Sequences 6-100+ Bases Long as B-1 Inhibitors	243889	21-May-93	253804	13-Jul-98		
GEN0036-00WO	Pending	PCT	Taxane Compounds, Compositions And Methods	PCT/US11/42289	29-Jan-11				
GEN0036-00AU	Pending	AU	Preparation of Testosterone and Related	AU20110271489	29-Jan-11				

GEN0046-00CA	Pending	CA	Compounds and Corresponding Synthesis Intermediate	CA2804031	29-Jun-11	
GEN0046-00CN	Pending	CN	Preparation of Testaxel and Related Compounds and Corresponding Synthesis Intermediate	CN2011835542	29-Jun-11	
GEN0046-00EA	Pending	EA	Taxane Compounds, Compositions and Methods	EA20120091486	29-Jun-11	
GEN0046-00EP	Pending	EP	Preparation of Testaxel and Related Compounds and Corresponding Synthesis Intermediate	EP11730832.0	29-Jun-11	
GEN0046-00MX	Pending	MX	Preparation of Testaxel and Related Compounds and Corresponding Synthesis Intermediate	MX201300219	29-Jun-11	
GEN0046-00SG	Pending	SG	Preparation of Testaxel and Related Compounds and Corresponding Synthesis Intermediate	SG201120009344	29-Jun-11	
GEN0046-00TW	Pending	TW	Taxane Compounds, Compositions and Methods	TW00123172	30-Jun-11	
GEN0046-00US	Pending	US	Taxane Compounds, Compositions and Methods	13/170,830	28-Jun-11	
GEN0046-01CF	Pending	US	Taxane Compounds, Compositions And Methods	13/455,455	25-Apr-12	
GEN0057-00TW	Pending	TW	Gallium Complexes, Pharmaceutical Compositions And Methods Of Use	TW01110105	25-Mar-12	
GEN0057-00US	Pending	US	Gallium Complexes, Pharmaceutical Compositions And Methods Of Use	13/426,877	22-Mar-12	
GEN0057-00WO	Pending	PCI	Gallium Complexes, Pharmaceutical Compositions And Methods Of Use	PCT/US12/00267	23-Mar-12	

TRADEMARKS

GEN0201CA-01	Registered	CA	GAMITE	1,099,932	17-Apr-01	TMA625338	12-Nov-04
GEN0201CA-02	Registered	CA	GAMITE	1,199,514	11-Dec-03	TMA606009	10-Aug-06
GEN0201EP-01	Registered	EP	GAMITE	2180297	18-Apr-01	2180297	30-Sep-02
GEN0201EP-02	Registered	EP	GAMITE	3458403	2-Nov-03	3458403	12-Apr-05
GEN0201MX-01	Registered	MX	GAMITE	635995	19-Dec-03	920315	30-Jun-01
GEN0201US-01	Registered	US	GAMITE	76240,253	15-Apr-01	3817880	14-Feb-04
GEN0201US-02	Registered	US	GAMITE	78179,744	29-Oct-02	2811752	11-May-04
GEN0212AT-01	Registered	AT	GENTA	354493	1-JUN-93	149802	29-Oct-93
GEN0212AU-01	Registered	AU	GENTA	715916	28-Nov-93	715916	8-Aug-97
GEN0212AU-02	Registered	AU	GENTA	826254	6-Mar-00	836254	24-May-01
GEN0212BR-01	Registered	BR	GENTA	817305181	4-Jun-93	817305181	29-Oct-96
GEN0212BX-01	Registered	BX	GENTA	298204	26-May-93	532563	28-May-93
GEN0212CA-01	Registered	CA	GENTA	730070	1-Jun-93	583752	13-Jun-03
GEN0212CA-02	Registered	CA	GENTA	1,199,163	8-Dec-03	730030	3-Nov-09
GEN0212CH-01	Registered	CH	GENTA	778119937	2-Jun-93	413765	2-Feb-95

GEN0212CH-02	Registered	CH	GENTA	540312003	26-Nov-03	517277	5-Feb-04
GEN0212CN-01	Registered	CN	GENTA	3910921	13-Feb-04	3910921	21-Aug-06
GEN0212EP-01	Registered	EU	GENTA	3458429	7-Nov-03	3458429	30-Mar-05
GEN0212FR-01	Registered	FR	GENTA	92470345	2-Jun-03	92470345	2-Jun-03
GEN0212GB-01	Registered	GB	GENTA	1527157	1-Jun-03	1527157	19-Jun-08
GEN0212HK-01	Registered	HK	GENTA	300208917	4-May-04	300208917	4-May-04
GEN0212IE-01	Registered	IE	GENTA	234793	4-Dec-02	157681	4-Dec-02
GEN0212IL-01	Registered	IL	GENTA	87547	31-May-03	87547	3-Oct-03
GEN0212MX-01	Registered	MX	GENTA	169562	3-Jun-03	575752	11-Mar-08
GEN0212MX-02	Registered	MX	GENTA	653996	19-Dec-03	882001	26-May-05
GEN0212NZ-01	Registered	NZ	GENTA	227404	31-May-03	227404	6-Aug-07
GEN0212NZ-02	Registered	NZ	GENTA	704187	10-Nov-03	704187	10-May-04
GEN0212PT-01	Registered	PT	GENTA	381332	19-May-04	381332W	9-May-05
GEN0212US-01	Registered	US	GENTA	743008219	3-Dec-89	1623172	20-Nov-90
GEN0212US-02	Registered	US	GENTA	75138647	12-Aug-96	2179179	4-Aug-98
GEN0212US-03	Registered	US	GENTA	78272784	10-Jul-03	2960378	30-Aug-05
GEN0213HL-01	Registered	IL	GENTA & Design	136091	22-Mar-00	136091	3-Apr-01
GEN0213HN-01	Pending	IN	GENTA & Design	1374513	28-Jul-05		
GEN0213KR-01	Registered	KR	GENTA & Design	40290543247	28-Sep-05	731111	13-Dec-07
GEN0217US-02	Registered	US	INNOVATION IN CANCER CARE	78733592	14-Oct-05	3217230	13-Mar-07
GEN0218US-02	Registered	US	KEEP APOPTOSIS ALIVE	770606618	14-Dec-06	22968586	25-Sep-07
GEN0218US-03	Registered	US	KEEP APOPTOSIS ALIVE	77204137	12-Jun-07	3483263	12-Aug-08
GEN0220AU-01	Registered	AU	S-SWIRL	1189115	1-Jun-07	1189115	29-Oct-07
GEN0220EP-01	Registered	EU	S-Swirl	5959614	1-Jun-07	5959614	30-Apr-08
GEN0222CA-01	Registered	CA	Sword Logo	1024116	15-Jun-04	TMA687694	14-May-07
GEN0222EP-01	Registered	EU	Sword Logo	50342304	29-Jan-04	519408	23-Mar-04
GEN0222JP-01	Registered	JP	Sword Logo	3613726	15-Jan-04	3613726	15-Jan-04
GEN0222US-01	Registered	US	Sword Logo	2004003553	15-Jan-04	4801631	10-Sep-03
GEN0222US-01	Registered	US	Sword Logo	78274255	15-Jul-05	2979018	26-Jul-05

Domain Names

- androgenics.biz
- androgenics.com
- antisense.bz
- antisense.cc
- antisense.tv
- antisense.ws
- bcl2.biz
- bcl2.com
- bcl2.net
- bcl2.tv

bcl2.us
gallium.tv
ganite.biz
ganite.bz
ganite.cc
ganite.com
ganite.info
ganite.net
ganite.org
ganite.tv
ganite.us
ganite.ws
genasen.us
genasens.us
genasense.biz
genasense.com
genasense.info
genasense.net
genasense.org
genasense.us
genasense.fr
genasenseandfluidara.com
genasenseandirmotecan.com
gensynergy.biz
gensynergy.bz
gensynergy.cc
gensynergy.com
gensynergy.info
gensynergy.net
gensynergy.org
gensynergy.tv
gensynergy.us
gensynergy.ws

375506/04_2

genta.bz
genta.cc
genta.com
genta.tv
genta.us
genta.ws
gentacare.com
gentacares.com
oblimersen.com
tesetaxel.cn.com
tesetaxel.com.tw
tesetaxel.eu
tesetaxel.eu.com
tesetaxel.info
tesetaxel.net
tesetaxel.org
tesetaxel.org.tw
tesetaxel.tw

Licenses

In-Licenses set forth on Schedule 2.1(d)



Query

Reports

Utilities

Logout

United States Bankruptcy Court
District of Delaware

Notice of Bankruptcy Case Filing

A bankruptcy case concerning the debtor(s) listed below was filed under Chapter 7 of the United States Bankruptcy Code, entered on 08/03/2012 at 2:01 PM and filed on 08/03/2012.

Genta Incorporated

200 Connell Drive

Berkeley Heights, NJ 07922

Tax ID / EIN: 33-0326866

aka **Genta Development Ltd.**



The case was filed by the debtor's attorney: The bankruptcy trustee is:

Donald J. Bowman, Jr.

Young, Conaway, Stargatt & Taylor

1000 North King Street

Wilmington, DE 19801

302-571-6600

George L. Miller

1628 John F. Kennedy Blvd.

Suite 950

Philadelphia, PA 19103-2110

215-561-0950

The case was assigned case number 12-12269-KG to Judge Kevin Gross.

In most instances, the filing of the bankruptcy case automatically stays certain collection and other actions against the debtor and the debtor's property. Under certain circumstances, the stay may be limited to 30 days or not exist at all, although the debtor can request the court to extend or impose a stay. If you attempt to collect a debt or take other action in violation of the Bankruptcy Code, you may be penalized. Consult a lawyer to determine your rights in this case.

If you would like to view the bankruptcy petition and other documents filed by the debtor, they are available at our *Internet* home page www.deb.uscourts.gov or at the Clerk's Office, 824 Market Street, 3rd Floor, Wilmington, DE 19801.

You may be a creditor of the debtor. If so, you will receive an additional notice from the court setting forth important deadlines.

David D. Bird
Clerk, U.S. Bankruptcy
Court